Evidence map›Paper›PMID 35266003›Full record

Trial reportEuropean heart journal2022

The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.

Michael R Zile, Akshay S Desai, Maria Rosa Costanzo, Anique Ducharme, Alan Maisel, Mandeep R Mehra, Sara Paul, Samuel F Sears, Frank Smart, Christopher Chien and 9 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03387813 (Hemodynamic-GUIDEd Management of Heart Failure), which is not on this map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03387813 nacompletednot on this map

Hemodynamic-GUIDEd Management of Heart Failure

TypeinterventionalSponsorAbbott Medical DevicesRan2018 to 2023Enrolled2,358ConditionsHeart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class IIArmsCardioMEMS™ HF System
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function.European heart journal supplements : journal of the European Society of Cardiology · 2025
    Article
  12. Article
  13. Indications for renal denervation in the treatment of hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Remote monitoring of cardiac implantable electronic devices and disease management.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 2 countries.

Michael R ZileDivision of Cardiology, Department of Medicine, RJH Department of Veterans Affairs Medical Center, Medical University of South Carolina, SC, USA.ORCID 0000-0001-7076-221X
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1443-0701
Maria Rosa CostanzoAdvocate Heart Institute, Naperville, IL, USA.ORCID 0000-0001-6995-7538
Anique DucharmeMontreal Heart Institute, Université de Montréal, Montreal, QC, Canada.ORCID 0000-0003-1681-9187
Alan MaiselUniversity of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-7467-0195
Mandeep R MehraCardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-8683-7044
Sara PaulCatawba Valley Health System, Conover, NC, USA.
Samuel F SearsEast Carolina University, Greenville, NC, USA.ORCID 0000-0002-7863-3591
Frank SmartSchool of Medicine, Louisiana State University, New Orleans, LA, USA.
Christopher ChienDivision of Cardiology, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0001-5425-6034
Ashrith GuhaCardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.
Jason L GuichardDepartment of Medicine, Division of Cardiology, Section for Advanced Heart Failure, Pulmonary Hypertension and Mechanical Circulatory Support, Prisma Health-Upstate, Greenville, SC, USA.ORCID 0000-0002-7381-5177
Shelley HallBaylor University Medical Center, Dallas, TX, USA.
Orvar JonssonSanford Health, Sioux Falls, SD, USA.
Nessa JohnsonAbbott, Abbott Park, IL, USA.ORCID 0000-0002-1020-6091
Poornima SoodAbbott, Abbott Park, IL, USA.
John HendersonAbbott, Abbott Park, IL, USA.
Philip B AdamsonAbbott, Abbott Park, IL, USA.ORCID 0000-0002-8974-9004
JoAnn LindenfeldVanderbilt Heart and Vascular Institute, Nashville, TN, USA.ORCID 0000-0001-9207-3634
Abbott (United States) · USBrigham and Women's Hospital · USAdvocate Heart Institute · USBaylor University Medical Center · USEast Carolina University · USHouston Methodist · USLouisiana State University · USMedical University of South Carolina · USMontreal Heart Institute · CAPrisma Health · USSanford Health · USUniversity of California San Diego · USUniversity of North Carolina at Chapel Hill · USValley Health System · USVanderbilt Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDuring the coronavirus disease 2019 (COVID-19) pandemic, important changes in heart failure (HF) event rates have been widely reported, but few data address potential causes for these changes; several possibilities were examined in the GUIDE-HF study. METHODS AND

resultsFrom 15 March 2018 to 20 December 2019, patients were randomized to haemodynamic-guided management (treatment) vs. control for 12 months, with a primary endpoint of all-cause mortality plus HF events. Pre-COVID-19, the primary endpoint rate was 0.553 vs. 0.682 events/patient-year in the treatment vs. control group [hazard ratio (HR) 0.81, P = 0.049]. Treatment difference was no longer evident during COVID-19 (HR 1.11, P = 0.526), with a 21% decrease in the control group (0.536 events/patient-year) and no change in the treatment group (0.597 events/patient-year). Data reflecting provider-, disease-, and patient-dependent factors that might change the primary endpoint rate during COVID-19 were examined. Subject contact frequency was similar in the treatment vs. control group before and during COVID-19. During COVID-19, the monthly rate of medication changes fell 19.2% in the treatment vs. 10.7% in the control group to levels not different between groups (P = 0.362). COVID-19 was infrequent and not different between groups. Pulmonary artery pressure area under the curve decreased -98 mmHg-days in the treatment group vs. -100 mmHg-days in the controls (P = 0.867). Patient compliance with the study protocol was maintained during COVID-19 in both groups.

conclusionDuring COVID-19, the primary event rate decreased in the controls and remained low in the treatment group, resulting in an effacement of group differences that were present pre-COVID-19. These outcomes did not result from changes in provider- or disease-dependent factors; pulmonary artery pressure decreased despite fewer medication changes, suggesting that patient-dependent factors played an important role in these outcomes. Clinical Trials.gov: NCT03387813.

Indexed as

COVID-19Heart FailureHemodynamicsHumansPandemicsPulmonary ArteryCOVID-19HaemodynamicsHeart failurePulmonary artery pressure

Identifiers

PMID35266003
PMCPMC8992324
OpenAlexW4213420086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.